Marketing authorization exploitation (MAE)

In addition to its status as a depositor, Alloga is a pharmaceutical laboratory that ensures the exploitation of medicines on behalf of companies holding marketing authorizations (MAE) that do not have pharmaceutical laboratory status in France. 
 

MAE exploitation


As an MAE exploitant, Alloga complies with the requirements of the Public Health Code and can carry out the following operations for your laboratory: 
 
  • Advertising operations
  • Wholesale sales or free transfers
  • Medical information operations
  • Pharmacovigilance
  • Batch tracking and batch withdrawal
  • Associated storage operations 
For any medical information, complaints, or pharmacovigilance questions regarding the specialties exploited by Alloga, please contact: +33 1 81 79 38 34. 
 

Learn more about our Exploitant services

Flexibility of processes


Depending on your needs, the exploitation of medicines and products can be carried out entirely by Alloga or jointly with your laboratory. 
 

Pharmacovigilance


Alloga France exploits a portfolio of products with marketing authorizations (MAE) as well as specific products. 
 
Healthcare professionals are required to immediately report any adverse effects suspected to be caused by a medicine to their Regional Pharmacovigilance Center (CRPV) or to the company exploiting the medicine. Since June 2011, patients and authorized patient associations can also contribute to pharmacovigilance by reporting any suspected adverse effects to their CRPV. 
 
If you have questions about one of our products or wish to report an adverse effect, whether or not it is mentioned in the leaflet or the Summary of Product Characteristics (SmPC), please contact us at: +33 1 81 79 38 34 (medical information service, available 24/7). 
 
You can also report an adverse effect to the CRPV corresponding to your place of residence by downloading the reporting form from the website of the National Agency for the Safety of Medicines and Health Products (ANSM): ansm.sante.fr. 
 
For any questions or comments, you can write to us at the following address: exploitant@alloga.fr  
 
For any medical issues, please consult your doctor. 
 

Marketed medicines


Alloga France provides information on the medicines it distributes as an exploitant holding a marketing authorization (MAE). 

 

MAE HOLDER PRODUCT NAME ACTIVE SUBSTANCE NAME CIP 13
AMPHASTAR PHARMACEUTICALS France BAQSIMI 3 mg, nasal powder in single-dose container Glucagon 34009 301 952 9 1
KARO PHARMA BURINEX 1 mg 30 scored tablets Bumetanide 34009 329 396 5 7
KARO PHARMA BURINEX 2 mg/4 ml 5 ampoules 4 ml FR Bumetanide 34009 328 584 2 2
KARO PHARMA BURINEX 5 mg 30 scored tablets Bumetanide 34009 345 213 9 3
KARO PHARMA CONDYLINE 0.5%, solution for cutaneous application Podophyllotoxin 34009 331 261 6 2
KARO PHARMA DELIPROCT, rectal ointment Prednisolone caproate, Cinchocaine hydrochloride 34009 313 954 3 0
KARO PHARMA DELIPROCT, suppository Prednisolone caproate, Cinchocaine hydrochloride 34009 302 888 4 9
COLGATE PALMOLIVE DENTEX, mouthwash solution Hydrogen peroxide 34009 354 007 9 6
COLGATE PALMOLIVE DURAPHAT 50 mg/ml, dental suspension Fluoride as sodium fluoride 34009 354 175 9 6
COLGATE PALMOLIVE DURAPHAT 500 mg/100 g, toothpaste Fluoride as sodium fluoride 34009 358 499 3 9
SAMSUNG BIOEPIS EPYSQLI 300 mg, solution for infusion Eculizumab 34009 550 962 4 5
KARO PHARMA FONX 1%, cream in 15 g tube Oxiconazole (nitrate) 34009 333 868 5 6
KARO PHARMA GYNO-PEVARYL 150 mg, ovule Econazole nitrate 34009 320 227 6 2
SOFIBEL FUMOUZE INONGAN, cream Methyl salicylate, Camphor 34009 341 589 4 0
KARO PHARMA KALEORID LP 1000 mg, 30 tablets Potassium (chloride) 34009 332 778 2 6
KARO PHARMA KALEORID LP 600 mg, 30 tablets Potassium (chloride) 34009 332 173 3 4
IMMUNOCORE KIMMTRAK 100 micrograms/0.5 mL, solution for infusion Tebentafusp 34009 550 891 6 2
KARO PHARMA LAMISIL 1%, cream 15 g Terbinafine hydrochloride 34009 301 588 9 0
KARO PHARMA LAMISIL 1%, solution for cutaneous spray Terbinafine hydrochloride 34009 355 855 3 0
KARO PHARMA LAMISILATE 1%, cream Terbinafine hydrochloride 34009 301 589 2 0
KARO PHARMA LAMISILATE MONODOSE 1%, solution for cutaneous application Terbinafine hydrochloride 34009 377 068 4 1
KARO PHARMA LAMISILDERMGEL 1%, gel Terbinafine 34009 350 018 6 3
KARO PHARMA PEVARYL 1%, cream Econazole nitrate 34009 318 522 4 7
KARO PHARMA PEVARYL 1%, fluid emulsion for local application Econazole nitrate 34009 320 225 3 3
KARO PHARMA PEVARYL 1%, powder for cutaneous application in a powder bottle Econazole nitrate 34009 334 236 2 9
KARO PHARMA PEVARYL 1 POUR CENT, solution for local application in spray bottle Econazole nitrate 34009 335 769 4 3
KARO PHARMA PEVISONE, cream Econazole nitrate, triamcinolone acetonide 34009 302 766 7 9
KARO PHARMA SELEXID 200 mg, 20 tablets Pivmecillinam (hydrochloride) 34009 301 049 3 4
KARO PHARMA SELEXID 200 mg, 28 tablets Pivmecillinam (hydrochloride) 34009 301 049 4 1
LAVIPHARM TRINIPATCH 10 mg/24 hours, transdermal device (44.8 mg / 14 cm²) Trinitrine 34009 338 073 0 6
LAVIPHARM TRINIPATCH 15 mg/24 hours, transdermal device (67.2 mg / 21 cm²) Trinitrine 34009 347 670 8 1
LAVIPHARM TRINIPATCH 5 mg/24 hours, transdermal device (22.4 mg / 7 cm²) Trinitrine 34009 338 072 4 5
KARO PHARMA ULTRAPROCT rectal ointment Fluocortolone trimethylacetate, fluocortolone caproate, cinchocaine hydrochloride 34009 313 917 0 8
KARO PHARMA ULTRAPROCT suppository Fluocortolone trimethylacetate, fluocortolone caproate, cinchocaine hydrochloride 34009 311 014 3 7

 

For the complete list of marketed medicines, please refer to the Public Medicines Database (BDPM) to access leaflets and Summaries of Product Characteristics (SmPC). 

Date of last update: November 18, 2024 PV/medical information contact: +33 1 81 79 38 34 (available 24/7).

Medical information charter


Quality and transparency of promotional information As part of our promotional information activities for healthcare professionals, our mission is to provide reliable, relevant, and compliant information in line with the marketing authorization (MAE) of the medicines presented, while encouraging their proper use. 

This activity is strictly regulated by the charter on information through canvassing or prospecting aimed at promoting medicines, revised on October 15, 2014. It is subject to annual certification based on the reference framework established by the French National Authority for Health (HAS). 

In 2024, Bureau Veritas renewed the certification of Alloga’s promotional information activity following a follow-up audit. This step represented a new opportunity to strengthen the expertise of our medical visitors, who ensure the quality of the information disseminated, as well as our overall operational excellence. It is part of an ethical and responsible approach aimed at ensuring compliance with our practices. 

More broadly, the quality of our promotional information reflects our commitment to a global quality approach, rooted in the company’s culture. It is shared within the relevant departments and continuously enriched through active monitoring of our environment and a dynamic of continuous improvement. 

For any comments on the quality of our promotional information activity, please contact us at: exploitant@alloga.fr  

Disclaimer 


The information provided does not replace consultation with a healthcare professional. 

Legal mentions 


In compliance with Law No. 2004-575 of June 21, 2004, on Confidence in the Digital Economy (LCEM), the following legal information is provided for transparency and to meet the requirements for publicly accessible websites: 

  • Company name: Alloga France
  • Registered address: 40, Boulevard de Dunkerque, CS 41221 - 13471 Marseille cedex 02
  • Share capital and legal form: SASU au capital de 5 000 000 €
  • RCS number: RCS Marseille B 582 118 675 00054
  • Other useful information:
  • Siret: B 582 118 675 00054
  • VAT number: TVA FR 582 118 675
  • ADEME: FR205825_01UJPD - CYCLAMED: FR205825_08DIBD
  • Contact details:
  • Phone: +33 4 91 28 15 00
  • Email: exploitant@alloga.fr   
  • Hosting provider:
  • Cencora Inc
  • 1 West First Ave
  • Conshohocken, PA 19428
  • United States 
  • https://www.cencora.com/contact-us